Your browser doesn't support javascript.
loading
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cocco, Emiliano; Lee, Ji Eun; Kannan, Srinivasaraghavan; Schram, Alison M; Won, Helen H; Shifman, Sophie; Kulick, Amanda; Baldino, Laura; Toska, Eneda; Arruabarrena-Aristorena, Amaia; Kittane, Srushti; Wu, Fan; Cai, Yanyan; Arena, Sabrina; Mussolin, Benedetta; Kannan, Ram; Vasan, Neil; Gorelick, Alexander N; Berger, Michael F; Novoplansky, Ofra; Jagadeeshan, Sankar; Liao, Yi; Rix, Uwe; Misale, Sandra; Taylor, Barry S; Bardelli, Alberto; Hechtman, Jaclyn F; Hyman, David M; Elkabets, Moshe; de Stanchina, Elisa; Verma, Chandra S; Ventura, Andrea; Drilon, Alexander; Scaltriti, Maurizio.
Afiliación
  • Cocco E; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. scaltrim@mskcc.org coccoe@mskcc.org chandra@bii.a-star.edu.sg venturaa@mskcc.org drilona@mskcc.org.
  • Lee JE; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kannan S; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Schram AM; Bioinformatics Institute (BII), Agency for Science, Technology and Research (A*STAR), Singapore.
  • Won HH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Shifman S; Weill Cornell Medical College, New York, New York.
  • Kulick A; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Baldino L; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Toska E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Arruabarrena-Aristorena A; Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kittane S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Wu F; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Cai Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Arena S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Mussolin B; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kannan R; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Vasan N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Gorelick AN; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
  • Berger MF; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
  • Novoplansky O; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
  • Jagadeeshan S; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Liao Y; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rix U; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Misale S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Taylor BS; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bardelli A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hechtman JF; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hyman DM; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Elkabets M; The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • de Stanchina E; Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida.
  • Verma CS; Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida.
  • Ventura A; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Drilon A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Scaltriti M; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
Cancer Discov ; 11(1): 126-141, 2021 01.
Article en En | MEDLINE | ID: mdl-33004339
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor trkA / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor trkA / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cancer Discov Año: 2021 Tipo del documento: Article